FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 262 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Job Loss During Cancer: How to Cope and Continue Treatment September 24, 2020 EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate February 20, 2026 Do Frequent Follow-Up Tests Benefit Colorectal Cancer Survivors? June 20, 2018 ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act June 11, 2025 Load more HOT NEWS EMA Adopts a Positive Opinion for a New Route of Administration... FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... As Winter Storms Plague Southern States, GreaterGood Is Helping Where It’s... Cancer Research UK spin-out gets US approval to trial unique T...
